These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35503499)

  • 1. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
    Okada AA; Takahashi K; Ohji M; Moon SC; Machewitz T; Sasaki K;
    Adv Ther; 2022 Jun; 39(6):2984-2998. PubMed ID: 35503499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
    Ohji M; Takahashi K; Okada AA; Kobayashi M; Matsuda Y; Terano Y;
    Adv Ther; 2020 Mar; 37(3):1173-1187. PubMed ID: 32016788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
    Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K;
    Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study.
    Ogura Y; Iida T; Lee WK; Cheung CMG; Mitchell P; Leal S; Schmelter T; Ishibashi T
    Jpn J Ophthalmol; 2021 May; 65(3):344-353. PubMed ID: 33474611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.
    Ohji M; Lanzetta P; Korobelnik JF; Wojciechowski P; Taieb V; Deschaseaux C; Janer D; Tuckmantel C
    Adv Ther; 2020 May; 37(5):2184-2198. PubMed ID: 32222903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
    Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
    BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.
    Garweg JG; Štefanickova J; Hoyng C; Niesen T; Schmelter T; Leal S; Sivaprasad S;
    Adv Ther; 2022 Jun; 39(6):2701-2716. PubMed ID: 35412227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
    Cohen SY; Dominguez M; Coscas F; Faure C; Baillif S; Oubraham H; Kodjikian L; Weber M;
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):959-969. PubMed ID: 36399178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.
    Korobelnik JF; Larsen M; Eter N; Bailey C; Wolf S; Schmelter T; Allmeier H; Chaudhary V
    Am J Ophthalmol; 2021 Jul; 227():106-115. PubMed ID: 33556381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
    Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S;
    Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
    Ogura Y; Terasaki H; Gomi F; Yuzawa M; Iida T; Honda M; Nishijo K; Sowade O; Komori T; Schmidt-Erfurth U; Simader C; Chong V;
    Br J Ophthalmol; 2015 Jan; 99(1):92-7. PubMed ID: 25107900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
    Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
    Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
    Lee WK; Iida T; Ogura Y; Chen SJ; Wong TY; Mitchell P; Cheung GCM; Zhang Z; Leal S; Ishibashi T;
    JAMA Ophthalmol; 2018 Jul; 136(7):786-793. PubMed ID: 29801063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.
    Inatani M; Higashide T; Matsushita K; Miki A; Ueki M; Iwamoto Y; Kobayashi M; Leal S;
    Adv Ther; 2021 Feb; 38(2):1116-1129. PubMed ID: 33330958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
    Marques JP; Farinha C; Costa MÂ; Ferrão Â; Nunes S; Silva R
    BMJ Open; 2017 Aug; 7(8):e015785. PubMed ID: 28851779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
    Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
    Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.